PALO ALTO, Calif. & SEATTLE--(BUSINESS WIRE)--Aug. 23,
2004--Agilent Technologies Inc. (NYSE:A) and Rosetta Biosoftware today
announced that Agilent -- the exclusive distributor of the Rosetta
Resolver and Rosetta Luminator gene-expression data analysis systems
-- has increased its commitment to the continued development and
enhancement of the Rosetta platforms. Agilent will provide these and
other informatics products both individually and as integrated
solutions to address existing and emerging life science applications.
"Our agreement with Agilent will benefit scientists who want to
correlate data from multiple domains on an enterprise-wide level,"
said Yelena Shevelenko, general manager of Rosetta Biosoftware.
"Together, Agilent and Rosetta will continue to provide improvements
in gene expression analysis such as the recently released Ratio
Splitter and Re-Ratio features, which give scientists a unique
flexibility to analyze two-color microarray data. Agilent's increased
investment makes it possible for us to bring these powerful
advancements to life scientists at an accelerated pace."
"Ultimately, researchers want to assimilate disparate data about
cell DNA, RNA, proteins, metabolites and pathways in order to develop
a more comprehensive understanding of disease function and that is the
focus of our new business unit," said Fran DiNuzzo, vice president and
general manager of Agilent's Integrated Biology Solutions unit.
"Integrated software is critical to the advancement of integrated
biology. We are increasing our investments in life science informatics
to facilitate these larger advances, and the Rosetta Resolver and
Luminator systems are an important part of our solutions."
About Rosetta Biosoftware
Rosetta Biosoftware is a leading provider of enterprise
bioinformatics solutions for life science research. Its enterprise
software solutions, including the Rosetta Resolver and Rosetta
Luminator gene-expression data analysis systems, empower life
scientists with advanced, scalable, and easy-to-use analysis platforms
that accelerate discovery research. Rosetta Biosoftware is a business
unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck &
Co., Inc. (NYSE:MRK). More information about Rosetta Biosoftware is
available at www.rosettabio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995. These statements involve risks and uncertainties, which may
cause results to differ materially from those set forth in the
statements. The forward-looking statements may include statements
regarding product development, product potential or financial
performance. No forward-looking statement can be guaranteed, and
actual results may differ materially from those projected. Neither
Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation
to publicly update any forward-looking statement, whether as a result
of new information, future events, or otherwise. Forward-looking
statements in this press release should be evaluated together with the
many uncertainties that affect the business of Merck & Co., Inc.
including, among others, the extent to which Rosetta Inpharmatics'
technology platform can be used in drug discovery programs,
uncertainty of market acceptance of Rosetta Inpharmatics'
technologies, ability to compete against existing technologies and
those mentioned in the cautionary statements in Item 1 of Merck's Form
10-K for the year ended Dec. 31, 2003, and in its periodic reports on
Form 10-Q and Form 8-K (if any) which are incorporated by reference.
About Agilent Technologies
Agilent Technologies Inc. (NYSE:A) is a global technology leader
in communications, electronics, life sciences and chemical analysis.
The company's 28,000 employees serve customers in more than 110
countries. Agilent had net revenue of $6.1 billion in fiscal year
2003. Information about Agilent is available on the Web at
www.agilent.com.
Forward-Looking Statements
This news release contains forward-looking statements (including,
without limitation, statements relating to Agilent's ability to invest
in the life sciences and to develop and provide informatics products)
that involve risks and uncertainties that could cause results of
Agilent Technologies to differ materially from management's current
expectations. These and other risks are detailed in the company's
filings with the Securities and Exchange Commission, including its
Quarterly Report on Form 10-Q for the quarter ended April 30, 2004.
The company assumes no obligation to update the information in this
press release.
Rosetta Resolver and Rosetta Luminator are U.S. registered
trademarks of Rosetta Inpharmatics.
NOTE TO EDITORS: Press releases, photography and other information
can be accessed on the Agilent Life Sciences and Chemical Analysis
newsroom at www.agilent.com/about/newsroom/lsca.
Further technology, corporate citizenship and executive news is
available on the Agilent news site at www.agilent.com/go/news.
CONTACT: Agilent Technologies Inc.
Christina Maehr, 408-553-7205
christina_maehr@agilent.com
or
Rosetta Biosoftware
E. Sasha Paegle, 206-926-1292
sasha_paegle@rosettabio.com
SOURCE: Agilent Technologies Inc.